 CAMBRIDGE, Mass., July 13, 2021 GLOBE NEWSWIRE -- Genocea Biosciences, Inc. Nasdaq: GNCA, a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase 12a clinical trial testing its GEN-011 therapy. GEN-011 represents a new category of autologous solid tumor cell therapy: neoantigen-targeted peripheral T cells NPTs. 